Anmeldung erfolgt in Kürze...
Details werden geladen...
Neutrolis Announces New England Journal of Medicine Publication Demonstrating First Clinical Evidence for NET-Degrading Therapy in Severe, Treatment-Refractory Systemic Lupus Erythematosus (SLE) Caus...
Treatment with investigational DNASE1L3 analog NTR-441, which degrades neutrophil extracellular traps (NETs), resulted in rapid clinical improvement in a patient with treatment-refractory SLE
Ähnliche Seiten
Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD) | The Manila Times
https://www.manilatimes.net/2026/06/22/tmt-newswire/globenewswire/prime-medicine-receives-us-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-pm359-for-the-treatment-of-chronic-granulomatous-disease-cgd/2370056Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity | The Manila Times
https://www.manilatimes.net/2026/07/09/tmt-newswire/globenewswire/rhythm-pharmaceuticals-announces-the-new-england-journal-of-medicine-publication-of-phase-3-transcend-trial-results-in-acquired-hypothalamic-obesity/2381259Groundbreaking Achievement: Study of Ensartinib as Postoperative Adjuvant Therapy Published in The New England Journal of Medicine | The Manila Times
https://www.manilatimes.net/2026/07/09/tmt-newswire/pr-newswire/groundbreaking-achievement-study-of-ensartinib-as-postoperative-adjuvant-therapy-published-in-the-new-england-journal-of-medicine/2381317BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia | The Manila Times
https://www.manilatimes.net/2026/06/29/tmt-newswire/globenewswire/bridgebio-announces-publication-in-the-new-england-journal-of-medicine-of-phase-3-propel-3-trial-of-oral-infigratinib-in-children-living-with-achondroplasia/2374430IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma | The Manila Times
https://www.manilatimes.net/2026/07/09/tmt-newswire/globenewswire/in8bio-announces-publication-in-the-journal-of-clinical-oncology-demonstrating-deltex-dri-doubles-progression-free-survival-in-newly-diagnosed-glioblastoma/2381560